hMG or Recombinant FSH on OHSS Prevention in PCOS Patients Undergoing IVF

• Status: Completed
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

There have been some controversies regarding the use of preparations with LH activity in patients with polycystic ovary syndrome (PCOS) who have high endogenous LH activity. In this research we aimed to compare urinary menotrophin versus recombinant FSH (rFSH) with respect to the prevention of OHSS

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zekai Tahir Burak Women's Health Research and Education Hospital
• Treatments: Menotropins

Criteria

Inclusion Criteria:

• Women with PCOS

Exclusion Criteria:

• Patients older than 38 years or with serum FSH level ≥12mIU/ml and a history of ovarian surgery were excluded from the study